Globin Solutions

What Globin Solutions does

Globin Solutions is a preclinical biotechnology company developing first-in-class recombinant heme-protein therapeutics for critical unmet needs in emergency medicine and transfusion science. Founded in 2017 by physician-scientists Jason Rose, Mark Gladwin, and Jesus Tejero at the University of Pittsburgh, the company is now headquartered in Baltimore, Maryland and operates with 1-10 employees. Its pipeline targets the absence of an approved carbon monoxide poisoning antidote (50,000 US emergency room visits annually, 2,000 deaths, 40% of survivors with permanent neurological deficits) and the chronic global shortage of donor blood. The lead candidate GSI-2311 (RcoM) is a next-generation engineered heme-protein CO scavenger with no hypertensive effect, GSI-1721 (Neuroglobin) holds FDA Orphan Drug Designation for CO poisoning, and GSI-2001 is a Pre-IND stage CO scavenger. The same platform underpins a GSI-2311-based artificial blood substitute addressing the $21B+ global blood substitutes market.

The company's core technology is a proprietary yeast-based manufacturing platform that produces complex heme proteins at >95% purity, solving a technical barrier that has historically limited the entire heme-protein therapeutics field. This platform enables in-house production, eliminating dependence on external CDMOs. Core technology was licensed from the University of Pittsburgh, and the company has completed three FDA regulatory interactions (2019 INTERACT, 2022 Pre-IND) and published extensively in PNAS, Science Translational Medicine, JBC, and JCI Insight. Strategic partners include UPMC Enterprises (lead Series A investor, 2018), PharmaDirections (regulatory consulting), and academic affiliates at the University of Pittsburgh and University of Maryland School of Medicine.

The business model is biopharmaceutical product sales following FDA approval: the CO poisoning antidote would be sold to hospital emergency departments through a direct sales force, and the artificial blood substitute would be distributed via pharmaceutical distribution networks targeting transfusion medicine centers globally. The company is pre-revenue and pre-commercial, currently raising a Series A2 extension round (initiated 2026) to fund IND-enabling studies, with total funding of approximately $7.25M+ across the 2018 Series A and 2020-2021 NIH/NIEHS grants.

Name

Globin Solutions

Legal name

Globin Solutions, Inc.

Website

https://globinsolutions.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Globin Solutions is a preclinical biotechnology company developing first-in-class recombinant heme-protein therapeutics — including a carbon monoxide poisoning antidote (FDA Orphan Drug Designation) and an artificial blood substitute — using a proprietary yeast manufacturing platform, targeting hospital emergency departments and transfusion medicine centers.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI)

akta.pro secondary industry

Transfusion Medicine & Immunohematology (Blood Bank) (HLAFAMAG)

Keywords

• Heme-protein therapeutics
• Carbon monoxide antidote
• Artificial blood substitute
• Recombinant protein engineering
• Biopharmaceutical drug development

Headquarters

HQ city

Pittsburgh

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Biopharmaceutical Product Sales: Pre-revenue biotech company developing heme-protein therapeutics. Expected revenue model is through commercialization of FDA-approved drugs for CO poisoning antidote and artificial blood substitute, sold to hospital emergency departments and transfusion medicine centers.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Globin Solutions develops first-in-class recombinant heme-protein therapeutics for emergency medicine and transfusion science. Its pipeline includes GSI-2311 (RcoM), GSI-1721 (Neuroglobin), and GSI-2001 as carbon monoxide poisoning antidotes, plus an artificial blood substitute, all produced via a proprietary yeast-based manufacturing platform achieving >95% purity.

Product overview

Globin Solutions is developing first-in-class recombinant heme-protein therapeutics through a platform-plus-products architecture. The proprietary yeast-based manufacturing platform enables consistent, high-yield production of complex heme proteins at >95% purity, serving as the foundational technology for three therapeutic programs: GSI-2311 (RcoM) as the lead next-generation heme therapeutic and CO scavenger, GSI-1721 (Neuroglobin) as an FDA Orphan Drug Designation CO poisoning antidote, and GSI-2001 as a CO scavenger at Pre-IND stage. The same platform enables development of an artificial blood substitute based on GSI-2311's oxygen-carrying properties. The portfolio addresses critical unmet needs in emergency medicine (no approved CO poisoning antidote exists) and transfusion science (donor blood expires in 42 days).

Differentiator

Problem solved

Functional benefit

Products and services

• GSI-2311 (RcoM) Next-generation engineered heme-protein therapeutic acting as a highly selective carbon monoxide scavenger with no hypertensive effect; lead active program in preclinical stage for emergency treatment of CO poisoning.
• GSI-1721 (Neuroglobin) Five-coordinate neuroglobin variant functioning as a high-affinity CO-binding ligand-trap antidote for carbon monoxide poisoning; received FDA Orphan Drug Designation.
• GSI-2001 Carbon monoxide scavenger therapeutic candidate at Pre-IND stage with multiple FDA regulatory interactions completed, targeting emergency CO poisoning treatment.
• GSI-2311-Based Oxygen Carrier (Artificial Blood Substitute) Recombinant heme-protein-based artificial blood substitute leveraging GSI-2311's oxygen-binding properties and engineered stability; addresses chronic global donor blood shortages and limitations such as the 42-day shelf life of donor blood.

Quantifiable outcome

• Carbon monoxide poisoning affects 50,000 Americans annually, causing 2,000 deaths
• +4 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• University of PittsburghcoreStrategic or Co-development PartnerTechnology licensed from University of Pittsburgh. Company co-founded by Jason Rose, Mark Gladwin, and Jesus Tejero who conducted pioneering research at Pitt's Vascular Medicine Institute. Represents fundamental IP origin for heme-protein therapeutics platform.
• University of Maryland School of MedicinecoreStrategic or Co-development PartnerCompany Chairman & Co-Founder Mark T. Gladwin serves as Dean of UMD School of Medicine. Co-Founder Jason Rose serves as Chief of Pulmonary, Critical Care, and Sleep Medicine and Associate Dean at UMD. Company headquarters located at UMD affiliation.
• PharmaDirectionsminorImplementation/ SI/ Consulting PartnerRegulatory consulting partnership providing CMC (Chemistry, Manufacturing and Controls) expertise for biologics, strategic program leadership for non-clinical development, and project management support for regulatory documentation.

Scale indicators9 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• CSL Behring: Global leader in blood plasma products and transfusion medicine, with a broad portfolio of biologic therapeutics. Comparable as a downstream commercial channel for blood substitutes and as an established incumbent with the commercial scale that Globin Solutions would need to partner with for distribution.
• Baxter International: Global medical products company with historical hemoglobin-based oxygen carrier programs (HemAssist). Comparable as both a historical competitor that exited the HBOC space due to safety issues and as a potential partner or acquirer of next-generation blood substitute technologies.
• Grifols: Major blood plasma products and transfusion medicine company with leading market share in hospital transfusion products. As a potential strategic acquirer or commercial partner for Globin Solutions' blood substitute program, it represents the most likely commercial exit path.
• Octapharma: Privately-held global blood plasma and recombinant protein therapeutics company. Comparable as both a potential competitor in transfusion medicine and as a strategic acquirer of novel blood substitute technologies like Globin Solutions' platform.
• Takeda Pharmaceutical: Global pharmaceutical company with rare disease and hematology franchises. Comparable as a potential large-pharma acquirer for a CO poisoning antidote with Orphan Drug Designation, particularly given Takeda's investment in rare hematology therapeutics.

Emerging players

• Velico Medical: Developer of spray-dried plasma technology for transfusion medicine, addressing the same unmet need that Globin Solutions' artificial blood substitute targets (donor blood limitations and stockpiling challenges). Comparable as an emerging alternative approach to the same blood availability problem.
• HbO2 Therapeutics: Developer of Hemopure, a hemoglobin-based oxygen carrier approved in South Africa for veterinary use and under investigation for human use. Closest active peer in the HBOC space, sharing the same fundamental therapeutic hypothesis as Globin Solutions' GSI-2311 oxygen carrier.
• Sangart: Historical developer of MP4OX (PEGylated hemoglobin) for oxygen delivery in trauma and surgical settings. While the company was acquired after mixed Phase II/III results, it represents the most directly comparable development program to Globin Solutions' blood substitute program in mechanism and indication.
• Diffusion Pharmaceuticals: Clinical-stage biotech developing oxygen diffusion-enhancing therapeutics for emergency medicine and oncology. Comparable as a similarly-staged small-cap biotech focused on oxygen-related therapeutics with emergency medicine applications, sharing similar capital markets dynamics and development timelines.
• Prolong Pharmaceuticals: Clinical-stage biotech developing PEGylated hemoglobin-based therapeutics for transfusion medicine. Directly comparable to Globin Solutions' artificial blood substitute program, with similar therapeutic area focus but more advanced clinical development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/globinsolutions

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Globin Solutions